Sagent Pharmaceuticals
 (SGNT)

- NASDAQ
What's your position on ?
Bullish
Bearish
Why are you ish?
Skip
Post
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • Wed, Jan. 13, 12:43 PM
    | Wed, Jan. 13, 12:43 PM | 24 Comments
  • Dec. 31, 2015, 6:03 PM
    • Sagent Pharma's (NASDAQ:SGNT) board has authorized the company to sell its Sagent (China) Pharmaceuticals unit, also known as SCP. (8-K filing)
    • Back in 2013, Sagent bought the 50% of SCP (then known as KSCP) it didn't own from JV partner Chegdu Kanghong Pharma for $25M. At the time, the company argued fully owning the business and its Chengdu, China manufacturing plant "better serves Sagent's long-term strategic goals, including a strategy of additional investment in product development and capacity expansion." Later that year, SCP began manufacturing an antineoplastic agent called Carboplatin.
    | Dec. 31, 2015, 6:03 PM
  • Dec. 22, 2015, 7:54 AM
    • Noting significant short interest and recent selloffs, analyst Randall Stanicky makes INSY and SGNT his top "out of consensus" picks for 2016. INSY's short interest is 46% of the float and SGNT's is 4.4%.
    • Though M&A will continue next year, there will be greater deal scrutiny and fewer targets, and Stanicky favors the targets vs. the accretive acquirers.
    • Mylan (NASDAQ:MYL) and Impax Labs (NASDAQ:IPXL) are seen as most likely to pursue "transformative" deals, while Teva (NYSE:TEVA), Perrigo (NYSE:PRGO), Sagent, Eagle (NASDAQ:EGRX), Depomed (NASDAQ:DEPO), and Endo (NASDAQ:ENDP) are likely to pursue bolt-on purchases.
    • Most likely targets: Akorn (NASDAQ:AKRX) and Flexion (NASDAQ:FLXN).
    • Top large-cap picks: Endo and Teva.
    • Related: 45% Upside For 2016's Top Takeover Target (Dec. 1)
    | Dec. 22, 2015, 7:54 AM | 3 Comments
  • Nov. 3, 2015, 7:15 AM
    • Sagent Pharmaceuticals (NASDAQ:SGNT): Q3 EPS of $0.01 beats by $0.07.
    • Revenue of $75.2M (+15.1% Y/Y) beats by $1.36M.
    | Nov. 3, 2015, 7:15 AM
  • Nov. 2, 2015, 5:30 PM
    | Nov. 2, 2015, 5:30 PM | 7 Comments
  • Aug. 4, 2015, 7:03 AM
    • Sagent Pharmaceuticals (NASDAQ:SGNT): Q2 EPS of -$0.01 misses by $0.06.
    • Revenue of $77.35M (+11.8% Y/Y) misses by $5.93M.
    | Aug. 4, 2015, 7:03 AM
  • Aug. 3, 2015, 4:33 PM
    • Sagent Pharmaceuticals (NASDAQ:SGNT) appoints Allan Oberman as CEO effective immediately upon receipt of a U.S. work visa. Previously, he was President & CEO of Teva Americas Generics.
    | Aug. 3, 2015, 4:33 PM
  • May 5, 2015, 7:11 AM
    • Sagent Pharmaceuticals (NASDAQ:SGNT): Q1 EPS of $0.04 in-line.
    • Revenue of $82.65M (+16.6% Y/Y) beats by $2.02M.
    | May 5, 2015, 7:11 AM
  • Apr. 16, 2015, 10:58 AM
    • Sagent Pharmaceuticals (SGNT +0.2%) promotes EVP, Chief Legal Officer and Corporate Secretary Michael Logerfo to President effective yesterday. He has been with the firm since 2007.
    | Apr. 16, 2015, 10:58 AM
  • Apr. 13, 2015, 7:04 AM
    • Sagent Pharmaceuticals (NASDAQ:SGNT) launches a 10 gram preservative-free pharmacy bulk package of vancomycin in the U.S. This complements its present offering of a 5 gram pharmacy bulk package.
    • The U.S. market for these products is ~$100M.
    | Apr. 13, 2015, 7:04 AM
  • Apr. 8, 2015, 1:38 PM
    • Cytori Therapeutics (CYTX -1.5%) rated Buy with a $7 (425% upside) price target by Maxim Group.
    • Sagent Pharmaceuticals (SGNT +9.2%) rated Buy with a $29 (13% upside) price target by Deutsche Bank.
    • Mylan (MYL +15.6%) rated Overweight with a $70 (2% upside) price target by JP Morgan.
    • Akorn (AKRX +3.7%) rated Buy with a $55 (11% upside) price target by Deutsche Bank.
    • OvaScience (OVAS +1.4%) rated Outperform with a $60 (102% upside) price target by Oppenheimer.
    • Impax Laboratories (IPXL +3.2%) rated Hold with a $50 (flat) price target by Deutsche Bank.
    • Catamaran (CTRX) downgraded to Hold with a $61.50 (4% upside) price target by Jefferies.
    • NewLink Genetics (NLNK +4.4%) downgraded to Hold with a $50 (11% downside risk) price target by Jefferies.
    • Stryker (SYK +0.4%) downgraded to Underweight with a $92 (flat) price target by Barclays.
    | Apr. 8, 2015, 1:38 PM | 5 Comments
  • Mar. 26, 2015, 5:39 PM
     
    • Top gainers, as of 5:15 p.m.: CMCM +12.8%. OXM +9.2%. SFY +4.9%. SGMS +4.3%. RICE +3.9%.
    • Top losers, as of 5:15 p.m.: WTI -6.6%. GME -5.7%. RH -5.1%. SGNT -3.9%. SSE -3.6%.
    | Mar. 26, 2015, 5:39 PM
  • Mar. 26, 2015, 12:49 PM
    | Mar. 26, 2015, 12:49 PM | 2 Comments
  • Mar. 26, 2015, 9:35 AM
    • Sagent Pharmaceuticals (SGNT -3%) Chairman and CEO Jeffrey Yordon informs the Board of Directors that he plans to retire from the firm, although he intends to remain a member of the Board.
    • Board member Frank Kung, Ph.D., has been named Chairman. A search for a new CEO will begin immediately.
    | Mar. 26, 2015, 9:35 AM
  • Feb. 19, 2015, 10:12 AM
    • Sagent Pharmaceuticals (SGNT +8.1%) Q4 results: Revenues: $84.4M (+31.7%); COGS: $59.9M (+28.0%); SG&A: $11.6M (+13.7%); Operating Income: $5.1M (+2.0%); Net Income: $30M (+733.3%); EPS: $0.91 (+727.3%).
    • FY2014 results: Revenues: $289.8M (+18.4%); COGS: $203.6M (+21.8%); SG&A: $43.2M (+19.3%); Operating Income: $19M (-39.5%); Net Income: $40.1M (+35.5%); EPS: $1.22 (+23.2%); Quick Assets: $74.1M (-52.5%).
    • 2015 Guidance: Net revenue: $325 - 375M; adjusted gross profit/net revenue: 27 - 31%; Operating expenses: $80M - 90M; Adjusted EBITDA: $20M - 30M; Net income: ($3M) - $13M.
    | Feb. 19, 2015, 10:12 AM
  • Feb. 19, 2015, 7:18 AM
    • Sagent Pharmaceuticals (NASDAQ:SGNT): Q4 EPS of $0.91 may not be comparable to consensus of $0.01.
    • Revenue of $84.36M (+31.6% Y/Y) beats by $8.2M.
    | Feb. 19, 2015, 7:18 AM
Company Description
Sagent Pharmaceuticals Inc is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing, sourcing and marketing injectable pharmaceutical products which it sells in the United States of America.
Sector: Healthcare
Industry: Drugs - Generic
Country: United States